These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 27384718)

  • 1. Advances in Bone-targeted Drug Delivery Systems for Neoadjuvant Chemotherapy for Osteosarcoma.
    Li CJ; Liu XZ; Zhang L; Chen LB; Shi X; Wu SJ; Zhao JN
    Orthop Surg; 2016 May; 8(2):105-10. PubMed ID: 27384718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surface engineering of nanoparticles with ligands for targeted delivery to osteosarcoma.
    Huang X; Wu W; Yang W; Qing X; Shao Z
    Colloids Surf B Biointerfaces; 2020 Jun; 190():110891. PubMed ID: 32114271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymeric Nanocarriers for Drug Delivery in Osteosarcoma Treatment.
    Gu X; Ding J; Zhang Z; Li Q; Zhuang X; Chen X
    Curr Pharm Des; 2015; 21(36):5187-97. PubMed ID: 26412359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic Evaluation of Drug-Loaded Hydrogels for Application in Osteosarcoma Treatment.
    Ali Gumustas S; Isyar M; Topuk S; Yilmaz I; Oznam K; Onay T; Ofluoglu O; Mahirogullari M
    Curr Pharm Biotechnol; 2016; 17(10):866-72. PubMed ID: 27194356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapies in bone sarcomas: current approach and future directions.
    Yarber JL; Agulnik M
    Expert Opin Investig Drugs; 2011 Jul; 20(7):973-9. PubMed ID: 21510829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research Progress of Nanomaterials in Chemotherapy of Osteosarcoma.
    Yu T; Cai Z; Chang X; Xing C; White S; Guo X; Jin J
    Orthop Surg; 2023 Sep; 15(9):2244-2259. PubMed ID: 37403654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics.
    Shi P; Cheng Z; Zhao K; Chen Y; Zhang A; Gan W; Zhang Y
    J Nanobiotechnology; 2023 Mar; 21(1):103. PubMed ID: 36944946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumoral-Lipid-Based Nanoparticles: a Platform for Future Application in Osteosarcoma therapy.
    González-Fernández Y; Imbuluzqueta E; Patiño-García A; Blanco-Prieto MJ
    Curr Pharm Des; 2015; 21(42):6104-24. PubMed ID: 26503148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone scaffolds-based localized drugs delivery for osteosarcoma: current status and future perspective.
    Liang W; Long H; Zhang H; Bai J; Jiang B; Wang J; Fu L; Ming W; Zhao J; Zeng B
    Drug Deliv; 2024 Dec; 31(1):2391001. PubMed ID: 39239763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteosarcoma: review of the past, impact on the future. The American experience.
    Jaffe N
    Cancer Treat Res; 2009; 152():239-62. PubMed ID: 20213394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies for the targeted delivery of therapeutics for osteosarcoma.
    Hughes DP
    Expert Opin Drug Deliv; 2009 Dec; 6(12):1311-21. PubMed ID: 19761419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy.
    Zhong J; Wen W; Wang J; Zhang M; Jia Y; Ma X; Su YX; Wang Y; Lan X
    Pharm Res; 2023 Jan; 40(1):231-243. PubMed ID: 36380167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrophages reduce the sensitivity of osteosarcoma to neoadjuvant chemotherapy drugs by secreting Interleukin-1 beta.
    Liang X; Guo W; Ren T; Huang Y; Sun K; Zhang H; Yu Y; Wang W; Niu J
    Cancer Lett; 2020 Jun; 480():4-14. PubMed ID: 32220541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of nanoparticles in drug delivery for the treatment of osteosarcoma: focussing on the liposomes.
    Liang W; Dong Y; Shao R; Zhang S; Wu X; Huang X; Sun B; Zeng B; Zhao J
    J Drug Target; 2022 Jun; 30(5):463-475. PubMed ID: 34962448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.
    Shaikh AB; Li F; Li M; He B; He X; Chen G; Guo B; Li D; Jiang F; Dang L; Zheng S; Liang C; Liu J; Lu C; Liu B; Lu J; Wang L; Lu A; Zhang G
    Int J Mol Sci; 2016 Apr; 17(4):506. PubMed ID: 27058531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug delivery nanocarriers and recent advances ventured to improve therapeutic efficacy against osteosarcoma: an overview.
    Desai SA; Manjappa A; Khulbe P
    J Egypt Natl Canc Inst; 2021 Feb; 33(1):4. PubMed ID: 33555490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model.
    Dutour A; Decouvelaere AV; Monteil J; Duclos ME; Roualdes O; Rousseau R; Marec-Bérard P
    J Nucl Med; 2009 Sep; 50(9):1533-40. PubMed ID: 19690032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapies in bone sarcomas.
    Scotlandi K; Picci P; Kovar H
    Curr Cancer Drug Targets; 2009 Nov; 9(7):843-53. PubMed ID: 20025572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-polymer nanoparticles with CD133 aptamers for targeted delivery of all-trans retinoic acid to osteosarcoma initiating cells.
    Gui K; Zhang X; Chen F; Ge Z; Zhang S; Qi X; Sun J; Yu Z
    Biomed Pharmacother; 2019 Mar; 111():751-764. PubMed ID: 30612000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J.
    Iwamoto Y; Tanaka K; Isu K; Kawai A; Tatezaki S; Ishii T; Kushida K; Beppu Y; Usui M; Tateishi A; Furuse K; Minamizaki T; Kawaguchi N; Yamawaki S
    J Orthop Sci; 2009 Jul; 14(4):397-404. PubMed ID: 19662473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.